Climb BioCLYM +3.32%22 Current Ratio is 27.86 as of Mar. 2026, which is 14% above its 10-year median of 24.45. GuruFocus rates CLYM with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Climb Bio ranks better than 95.83% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Climb Bio's current ratio for the quarter that ended in Mar. 2026 was 27.86.
Climb Bio has a current ratio of 27.86. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Climb Bio's Current Ratio or its related term are showing as below:
CLYM'
s Current Ratio Range Over the Past 10 Years
Min: 7.18 Med: 24.45 Max: 60.41
Current: 27.86
During the past 7 years, Climb Bio's highest Current Ratio was 60.41. The lowest was 7.18. And the median was 24.45.
CLYM's Current Ratio is ranked better than 95.83% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs CLYM: 27.86
Climb Bio (NAS:CLYM) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Climb Bio Current Ratio Related Terms
Climb Bio Current Ratio Historical Data
* Premium members only.
The historical data trend for Climb Bio's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYM vs ACRS, CABA, IMMX: Current Ratio Comparison
For the Biotechnology subindustry, Climb Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Climb Bio Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Climb Bio's Current Ratio distribution charts can be found below:
* The bar in red indicates where Climb Bio's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Climb Bio (CLYM) has a Current Ratio of 27.86 as of Mar. 2026. This is 14% above median its historical median of 24.45. Over the past decade, Climb Bio's Current Ratio has ranged from 7.18 to 60.41. According to the industry distribution chart, Climb Bio ranks #59 out of 1416 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Climb Bio's Current Ratio too high?
Climb Bio's current Current Ratio of 27.86 is 14% above median its 10-year median of 24.45. Over the past 10 years, this metric has ranged from a low of 7.18 to a high of 60.41. The Biotechnology industry median Current Ratio is 3.89. Climb Bio's value of 27.86 is 617.1% above this industry median. Based on the distribution chart, Climb Bio ranks #59 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Climb Bio has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Climb Bio's Current Ratio compare to ACRS and CABA?
According to the Biotechnology industry distribution chart, Climb Bio ranks #59 out of 1416 companies for Current Ratio. This places Climb Bio in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Climb Bio's value of 27.86 is 617.1% above this benchmark. Historically, Climb Bio's own Current Ratio has ranged from 7.18 to 60.41 over the past decade. While the company's 10-year median is 24.45 vs. the industry median of 3.89, Climb Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Climb Bio's current Current Ratio of 27.86 is 617.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Climb Bio's current Current Ratio is 27.86, which is 14% above median its own 10-year median of 24.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Climb Bio stock overvalued right now?
Climb Bio (CLYM) has a current Current Ratio of 27.86. The current Current Ratio is 27.86, which is 14% above median its 10-year median of 24.45 and 617.1% above the Biotechnology industry median of 3.89. Climb Bio's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Climb Bio (CLYM), the current Current Ratio is 27.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
22GF Score
Get the complete analysis for CLYM
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYM has been successfully added to your 
